Perrigo (PRGO) Research & Development (2012 - 2026)
Perrigo (PRGO) posted quarterly Research & Development of $24.6 million for Q1 2026, down 83.17% year-over-year from $146.2 million in Q1 2025, and up 12.84% quarter-over-quarter from $21.8 million in Q4 2025.
Perrigo (PRGO) Research & Development (2012 - 2026) Analysis & Trends
Perrigo (PRGO) has reported Research & Development for 15 consecutive years, with $24.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 83.17% year-over-year to $24.6 million; the TTM figure through Mar 2026 stood at $195.7 million (down 75.05% YoY), while the FY2025 annual figure was $95.4 million, down 82.55% from the prior year.
- Research & Development improved to $24.6 million in Q1 2026 per PRGO's latest filing, from $21.8 million in the prior quarter.
- Across five years, Research & Development topped out at $462.2 million in Q4 2024 and bottomed at -$366.7 million in Q4 2023.
- Historically, Research & Development has averaged $51.5 million across 5 years, with a median of $31.5 million in 2022.
- On a YoY basis, Research & Development climbed as much as 389.62% in 2025 and fell as far as 95.28% in 2025.
- Perrigo's Research & Development stood at -$307.9 million in 2022, then fell by 19.1% to -$366.7 million in 2023, then soared by 226.04% to $462.2 million in 2024, then plunged by 95.28% to $21.8 million in 2025, then rose by 12.84% to $24.6 million in 2026.
- Business Quant data shows PRGO's Research & Development at $24.6 million in Q1 2026, $21.8 million in Q4 2025, and $127.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 970.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -1.05 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 146.30 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 248.30 Mn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 326.70 Mn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 92.00 Mn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Perrigo | 1.88 Bn | 1.48 Bn | 313.90 Mn | 129.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | 129.50 Mn |
| Mar 28, 2026 | 24.60 Mn |
| Dec 31, 2025 | 21.80 Mn |
| Sep 27, 2025 | 127.30 Mn |
| Jun 28, 2025 | 22.00 Mn |
| Mar 29, 2025 | 146.20 Mn |
| Dec 31, 2024 | 462.20 Mn |
| Sep 28, 2024 | 26.00 Mn |
| Jun 29, 2024 | 150.10 Mn |
| Mar 30, 2024 | 150.30 Mn |
| Dec 31, 2023 | -366.70 Mn |
| Sep 30, 2023 | 150.20 Mn |
| Jul 1, 2023 | 32.20 Mn |
| Apr 1, 2023 | 31.10 Mn |
| Dec 31, 2022 | -307.90 Mn |
| Oct 1, 2022 | 144.50 Mn |
| Jul 2, 2022 | 31.50 Mn |
| Apr 2, 2022 | 29.30 Mn |
| Dec 31, 2021 | -283.00 Mn |
| Oct 2, 2021 | 129.70 Mn |